Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesShort InterestTrends About Neurotrope Stock (NASDAQ:NTRP) 30 days 90 days 365 days Advanced Chart Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Neurotrope alerts:Sign Up Key Stats Today's Range$1.54▼$1.5950-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume8,056 shsAverage Volume33,263 shsMarket Capitalization$2.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRP Stock News HeadlinesNextTrip (NASDAQ:NTRP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNextTrip, Inc.: NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for GroupsAugust 2, 2024 | finanznachrichten.deTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 21, 2024 | Colonial Metals (Ad)NextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip Inc NTRPApril 4, 2024 | morningstar.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAugust 17, 2023 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 22, 2022 | finance.yahoo.comSee More Headlines NTRP Stock Analysis - Frequently Asked Questions How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) issued its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE). Company Calendar Last Earnings10/30/2018Today11/21/2024Next Earnings (Estimated)1/21/2025Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Transportation services Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax Margin-904.14% Return on Equity-286.56% Return on Assets-100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.27 Sales & Book Value Annual Sales$630,000.00 Price / Sales3.54 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.47Miscellaneous Outstanding Shares1,420,000Free Float1,283,000Market Cap$2.23 million OptionableNo Data Beta1.67 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:NTRP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.